Published by Hytanbio Tech · Technical guide · 31 October 2026
A peptide name identifies a sequence, but a purchase order also needs to identify the supplied salt form. Material isolated after reversed-phase purification may carry acetate or trifluoroacetate (TFA) as a counterion. The choice affects what is in the weighed powder and how a result should be reported. A quote that says only “95% peptide” leaves that question open.
Why the counterion belongs in the specification
Basic groups on a peptide can associate with anions from the purification or exchange process. The United States Pharmacopeia (USP) maintains separate procedures for acetic acid in peptides, General Chapter <503>, and TFA in peptides, General Chapter <503.1>. Their existence is a useful reminder that counterion content is a measured attribute, not an assumption based on the peptide name.
Two quotations for the same sequence may refer to different forms. “Acetate” in a product title does not by itself tell a buyer the measured acetate content or the basis of the assay. Ask for the actual specification and the batch method. The same caution applies when comparing a powder sold by total gross mass with one quoted on a net peptide basis.
Keep three numbers separate
- Chromatographic purity: the share of the relevant chromatographic peak area under a stated method. It does not describe all non-peptide material in the vial.
- Counterion and water: separate components that can contribute to powder mass and may require their own tests.
- Peptide content or assay: the amount of target peptide under a defined calculation and reference-standard basis.
For a detailed reading of the analytical terms, see our guide to HPLC purity, assay and LC-MS identity. The USP authors’ paper on synthetic-peptide reference standards also discusses why moisture and counterions matter when assigning reference-standard content.
What to request before changing salt form
A request to exchange TFA for acetate is a process change. It may alter the impurity profile, apparent solubility or concentration calculation, so the supplier should confirm feasibility for the particular sequence. A buyer should state the intended end use and identify the attributes that must remain comparable. “TFA-free” needs a defined analytical meaning and an agreed acceptance limit; it should not be inferred from a marketing phrase.
- State the exact sequence, terminal modifications and requested salt form.
- Ask how counterion content is measured and reported for the offered lot.
- Agree whether the quoted assay is on an as-is, anhydrous or peptide-base basis.
- Compare the salt-exchanged sample with the previous material for identity, related impurities and any relevant functional attributes.
- Record the lot-specific result in the purchase specification and COA request.
The EMA guideline on synthetic medicinal peptides discusses counterions and analytical control in a regulated medicine context. Its methods are informative for technical discussions; it does not automatically impose medicinal-product requirements on a cosmetic or research raw material.
Frequently asked questions
Does 95% HPLC purity mean 95% peptide by weight?
No. HPLC area purity is method-dependent and does not by itself account for water, counterions or other non-chromatographic components. Request a separate assay basis when mass balance matters.
Can a buyer specify acetate instead of TFA?
Yes, as a project requirement. The supplier must assess whether exchange is feasible for the sequence and confirm the resulting specification and method.
Is one counterion universally better?
No. The relevant decision depends on the sequence, intended formulation, target market and measured material attributes. The name of the counterion alone is not a stability or safety result.
References and scope
- USP-NF General Chapter <503>, Acetic Acid in Peptides.
- USP-NF General Chapter <503.1>, TFA in Peptides.
- USP authors, Reference Standards to Support Quality of Synthetic Peptide Therapeutics.
- EMA, Guideline on the Development and Manufacture of Synthetic Peptides (effective 2026).
Editorial scope: This guide is a procurement and analytical discussion. Product acceptance depends on the agreed specification and the relevant batch documentation. For a project review, send the sequence, target salt form and intended use through our technical enquiry.